UNSPSC 51411903: Emopamil

This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M514041RF7. European Medicines Agency schedules Emopamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06510MIG. Emopamil generally arises in the molecular formula C23H30N2. The term EMOPAMIL is an International Non-Proprietary Name or INN. EMOPAMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule emopamil under HS 29269095 and SITC 51484. As of Q4 2014, EMOPAMIL remains the US FDA Preferred Term for this commodity. Emopamil bears US NLM identifiers UMLS ID C0059080 and NCI Concept Code C74417. SMILES: N(CCCC(C(C)C)(c1ccccc1)C#N)(CCc1ccccc1)C.

UNSPSC 51411903 Emopamil is a Commodity code representing pharmaceutical active ingredients and finished-form medications procured by state and local health agencies, emergency services, and cooperative purchasing programs. State and local governments use this code to source specific medications for emergency medical systems, hospital formularies, and public health programs — in recent activity, this includes advanced life support medications for fire rescue services, generic pharmaceuticals for state agency and local government facilities through cooperative agreements, and direct-to-manufacturer prescription programs managed by state health commissions. The issuing bodies span city purchasing departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving state and local participants across multiple jurisdictions).

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) due April 8, 2026, for Advanced Life Support Medications including epinephrine, labetalol, adenosine, and diltiazem vials with an estimated contract value of $40,000.00 and a Small Local Business Enterprise sheltered-market 5 percent bid discount; the Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with contract terms of two years plus optional extensions and vendor pricing weighted 75 percent in evaluation; and the Texas Health and Human Services Commission posted an RFI (HHS0017013) with a response deadline of April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription program capabilities without disclosing specific award values or budget ranges at that exploratory stage.